 <h1>Sodium polystyrene sulfonate Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to sodium polystyrene sulfonate: oral or rectal powder for suspension, oral or rectal suspension</i></p><p>Side effects include:</p><p>Gastric irritation,    anorexia,    constipation,    diarrhea,    fecal impaction,    GI concretions (bezoars),   nausea,    vomiting,    hypokalemia,   hypocalcemia,   hypomagnesemia,  clinically important sodium retention.  </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to sodium polystyrene sulfonate: oral suspension, oral and rectal powder, oral and rectal suspension, rectal enema</i></p><h3>Gastrointestinal</h3><p><b>Rare</b> (0.01% to 0.1%): Intestinal/colonic necrosis</p><p><b>Frequency not reported</b>: Gastric irritation, nausea, vomiting, constipation, diarrhea, fecal impaction, intestinal obstruction, other serious gastrointestinal (GI) adverse reactions</p><p><b>Postmarketing reports</b>: GI concretions/bezoars, ischemic colitis, GI tract ulceration, intestinal perforation, GI stenosis<sup>[Ref]</sup></p><p>Nausea, vomiting, and constipation have occurred, especially with high doses.  In clinical trials, fecal impaction occurred in geriatric patients given large doses; children have experienced impaction with rectal administration.  Following oral administration, intestinal obstruction with aluminum hydroxide concretions and bezoar formation occurred in neonates.  In postmarketing reports, gastrointestinal tract ulcerations, necrosis, and ischemic colitis may have resulted in intestinal perforation.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Anorexia, hypokalemia, hypocalcemia, hypomagnesemia, significant sodium retention<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Postmarketing reports</b>: Grand mal seizure<sup>[Ref]</sup></p><p>A grand mal seizure occurred in 1 patient with renal dysfunction and concomitant use of this drug and magnesium hydroxide.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Postmarketing reports</b>: Acute bronchitis, bronchopneumonia<sup>[Ref]</sup></p><p>Bronchitis with/without pneumonia occurred after inhalation of particles of this drug.<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Kayexalate (sodium polystyrene sulfonate)." Sanofi Winthrop Pharmaceuticals, New York, NY. </p><h2>More about sodium polystyrene sulfonate</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>7 Reviews</li>
<li>Drug class: cation exchange resins</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Sodium polystyrene sulfonate &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Sodium polystyrene sulfonate Rectal &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hyperkalemia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>